Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
Recombinant Cynomolgus IL-23 alpha & Mouse IL-12 beta Heterodimer Protein, His Tag&Tag Free, 50 µg  

Recombinant Cynomolgus IL-23 alpha & Mouse IL-12 beta Heterodimer Protein, His Tag&Tag Free, 50 µg

Recombinant Cynomolgus IL-23 alpha & Mouse IL-12 beta Heterodimer Protein, AA Val 22 - Pro 189 (IL23A) & Met 23 - Ser 335 (IL12B), expressed from human 293 cells (HEK293), His Tag&Tag Free

Synonym: recombinant, IL-23 alpha & IL-12 beta

More details

ILB-CM52W8-50

Availability: within 7 days

455,00 €

Background
Interleukin-23 subunit alpha (IL-23 alpha) can associates with IL12B to form the IL-23 interleukin, a heterodimeric cytokine which functions in innate and adaptive immunity. IL-23 may constitute with IL-17 an acute response to infection in peripheral tissues. IL-23 binds to a heterodimeric receptor complex composed of IL12RB1 and IL23R, activates the Jak-Stat signaling cascade, stimulates memory rather than naive T-cells and promotes production of proinflammatory cytokines. IL-23 induces autoimmune inflammation and thus may be responsible for autoimmune inflammatory diseases and may be important for tumorigenesis.

Source
Recombinant Cynomolgus IL-23A & Mouse IL-12B Heterodimer Protein, His Tag&Tag Free (ILB-CM52W8) is expressed from human 293 cells (HEK293). It contains AA Val 22 - Pro 189 (IL23A) & Met 23 - Ser 335 (IL12B) (Accession # A0A2K5TLV4-1 (IL23A) & P43432-1 (IL12B)).
Predicted N-terminus: His (IL23A) & Met 23 (IL12B)

Molecular Characterization
Cynomolgus IL-23A & Mouse IL-12B Heterodimer Protein, His Tag&Tag Free, produced by co-expression of IL-23 alpha and IL-12 beta, has a calculated MW of 20.3 kDa (IL-23 alpha) and 35.8 kDa (IL-12 beta). Subunit IL-23 alpha is fused with a polyhistidine tag at the N-terminus and subunit IL-12 beta contains no tag. The reducing (R) protein migrates as 20-23 kDa (IL-23 alpha) and 40-42 kDa and 43-46 kDa (IL-12 beta) respectively due to glycosylation.

Endotoxin
Less than 1.0 EU per μg by the LAL method.
 
Purity
>90% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization.

Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
-20°C to -70°C for 12 months in lyophilized state;
-70°C for 3 months under sterile conditions after reconstitution.

Bioactivity
Please refer to product data sheet.

References

(1) "Cytokine RNA In Situ Hybridization Permits Individualized Molecular Phenotyping in Biopsies of Psoriasis and Atopic Dermatitis"
Wang, Fogel, Murphy et al
JID Innov (2021) 1 (2), 100021
(2) "Predicted regulatory SNPs reveal potential drug targets and novel companion diagnostics in psoriasis"
Ruiz Ramírez, Flores-Saiffe Farías, Chávez Álvarez et al
J Transl Autoimmun (2021) 4, 100096
(3) "Interplay between NOD1 and TLR4 Receptors in Macrophages: Nonsynergistic Activation of Signaling Pathways Results in Synergistic Induction of Proinflammatory Gene Expression"
Budikhina, Murugina, Maximchik et al
J Immunol (2021) 206 (9), 2206-2220
Showing 1-3 of 62 papers.